Effect of sodium–glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis

被引：0
作者：
Mohammad Fakhrolmobasheri
Amir Parsa Abhari
Behrad Manshaee
Maryam Heidarpour
Davood Shafie
Ehsan Mohammadbeigi
Amir Mohammad Mozafari
Sadegh Mazaheri-Tehrani
机构：
[1] Isfahan University of Medical Sciences,Heart Failure Research Center, Isfahan Cardiovascular Research Institute
[2] Isfahan University of Medical Sciences,Isfahan Endocrine and Metabolism Research Center
[3] Isfahan University of Medical Sciences,Student Research Committee, School of Medicine
[4] Isfahan University of Medical Sciences,Medical Library and Information Sciences Department, Health Information Technology Research Center, School of Management and Medical Information Sciences, Isfahan University of Medical Sciences
[5] Shahrekord University of Medical Sciences,Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non
[6] Isfahan University of Medical Sciences,Communicable Disease
来源：
Acta Diabetologica | 2023年 / 60卷
关键词：
Sodium–glucose cotransporter 2 inhibitors; Dapagliflozin; Empagliflozin; Insulin resistance; Insulin sensitivity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 202
页数：11
相关论文
共 144 条
[1]  
Roth GA(2020)Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study J Am Coll Cardiol 76 2982-3021
[2]  
Mensah GA(2017)An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus Curr Opin Endocrinol Diabetes Obes 24 73-79
[3]  
Johnson CO(2020)SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control Nat Rev Cardiol 17 761-772
[4]  
Addolorato G(2017)SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study J Diabetes Metab Disord 16 27-128
[5]  
Ammirati E(2022)The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: a systematic review and meta-analysis Front Pharmacol 13 121-320
[6]  
Baddour LM(2018)Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization Adipocyte 7 312-861
[7]  
Hsia DS(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 372 843-2041
[8]  
Grove O(2022)Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open-label, noninferiority trial Diabetes Obes Metab 24 2036-235
[9]  
Cefalu WT(2021)Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial Diabetes Ther 12 229-813
[10]  
Cowie MR(2016)Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes Diabetes Care 39 37-305
12345678910